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Background: Hemofiltration rate, changes in blood and ultrafiltration flow, and discrepancies 
between the prescribed and administered doses strongly influence pharmacokinetics (PK) and 
pharmacodynamics (PD) of antimicrobial agents during continuous veno-venous hemofiltration 
(CVVH) in critically ill patients. Methods: Ancillary data were from the prospective multicenter 
IVOIRE (hIgh VOlume in Intensive caRE) study. High volume (HV, 70 mL/kg/h) was at 
random compared with standard volume (SV, 35 mL/kg/h) CVVH in septic shock patients 
with acute kidney injury (AKI). PK/PD parameters for all antimicrobial agents used in each 
patient were studied during five days. Results: Antimicrobial treatment met efficacy targets 
for both percentage of time above the minimal inhibitory concentration and inhibitory quotient. 
A significant correlation was observed between the ultrafiltration flow and total systemic 
clearance (Spearman test: P < 0.005) and between CVVH clearance and drug elimination 
half-life (Spearman test: P < 0.005). All agents were easily filtered. Mean sieving coefficient 
ranged from 38.7% to 96.7%. Mean elimination half-life of all agents was significantly shorter 
during HV-CVVH (from 1.29 to 28.54 h) than during SV-CVVH (from 1.51 to 33.85 h) (P < 
0.05). Conclusions:This study confirms that CVVH influences the PK/PD behavior of most 
antimicrobial agents. Antimicrobial elimination was directly correlated with convection rate. 
Current antimicrobial dose recommendations will expose patients to underdosing and increase 
the risk for treatment failure and development of resistance. Dose recommendations are 
proposed for some major antibiotic and antifungal treatments in patients receiving at least 25 
mL/kg/h CVVH.
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INTRODUCTION
Adequate antimicrobial therapy is essential to maximize the 
survival of  critically ill patients.[1] Anti-infective drugs are 
classified as time-dependent (e.g., β-lactams, carbapenems, 
macrolides, fluconazole, vancomycin) when their 
bactericidal effect depends on the time that plasma levels 
remain above a threshold minimal inhibitory concentration 
(MIC), or concentration-dependent (e.g., aminoglycosides, 
fluoroquinolones, echinocandins, daptomycin, polyenes, 
doxycyclin) when the height of  peak concentration above 
the MIC determines the killing effect.[2] Acute kidney injury 
(AKI) significantly interferes with the administration of  
anti-infective agents. Antibacterial pharmacokinetics (PK) 
are affected by AKI itself, the underlying or accompanying 
disease process, and the applied renal replacement therapy. 
Continuous renal replacement therapy (CRRT) causes 
alterations in drug clearance. Factors influencing PK and 
pharmacodynamics (PD) of  antimicrobial drugs during 
CRRT include the CRRT mode (diffusion, convection, 
or both), changes in blood and ultrafiltration flow, type 
of  filtration membrane (e.g., highly adsorptive filters), and 
discrepancies between prescribed and actually administered 
antimicrobial dose. For these reasons, drug dose adjustment 
in critically ill patients receiving CRRT is challenging.[3,4,5] 
Continuous veno-venous hemofiltration (CVVH) is the 
most commonly used CRRT technique in the critical care 
setting.[5] Antimicrobial drug behavior during CVVH is 
still scarcely documented. This is of  concern because 
higher ultrafiltrate doses are increasingly promoted.[7,8,9]. 
Moreover, great divergence exist between predicted and 
observed removal of  antibiotics in critically ill CVVH-
treated patients.[10] 
We applied the established PK/PD principles in a subgroup 
of  patients from the previously published IVOIRE trial, 
which compared high volume (HV; 70 mL/kg/h) with 
standard volume (SV; 35 mL/kg/h) CVVH in septic 
shock patients with AKI.[11] Importantly, the IVOIRE 
trial was conceived in 2004 when PK/PD knowledge 
was still in its infancy. At that time, no consensus existed 
regarding antimicrobial dosing during HV-CVVH. Also, 
the primary endpoint of  the IVOIRE study was comparing 
the 28-day mortality between the patients treated with 
HV-CVVH and SV-CVVH. Therefore, upfront use of  
higher antimicrobial doses in the HV-CVVH group 
was not supported because it was thought to produce 
substantial outcome bias. It was decided to administer all 
drugs according to the accepted dose recommendations at 
that time (i.e., weight-adapted, as in patients without AKI) 
and to treat both SV-CVVH and HV-CVVH patients with 
comparable doses of  antimicrobials either in continuous 
or intermittent infusion. 
The current study is aimed to assess whether a different 
convection rate determines antimicrobial PK behavior 
during CVVH. The study results also allowed to create dose 
recommendations for some of  the most commonly used 
antimicrobials in critically ill patients receiving a CVVH 
dose of  at least 25 mL/kg/h.  
PATIENTS AND METHODS
Patients
PK/PD parameters of  all administered antimicrobial 
agents were evaluated in a subgroup of  patients who 
completed a 96 h therapy within the scope of  the IVOIRE 
study. All observations were made abiding the standard 
routine patient care incorporated within the IVOIRE study 
protocol.[11] The Institutional Ethical Committee waived a 
formal approval procedure. 
Hemofiltration Technique
A 14F coaxial double lumen hemofiltration catheter was 
inserted either in the right internal jugular vein or in the 
femoral veins. CVVH was performed using an Aquarius® 
hemofiltration circuit (Edwards Life Sciences), with a 1.9 m2 
Aquamax® polyethersulfone filter (Edwards Life Sciences). 
Since this filter is non-adsorptive, antibiotic elimination is 
determined by ultrafiltration alone. Hemofiltration treatment 
was initiated according to randomization towards either SV-
CVVH or HV-CVVH. Blood flow rate was adapted to obtain 
a filtration fraction ≤ 25%. Anticoagulation was ensured 
by non-fractionated heparin. Filters were changed every 
48 h or in case of  early clotting. Substitution was divided 
in a 1/3–2/3 proportion between pre- and post-dilution. 
Patients who still required CVVH at the end of  the study 
were continued on standard hemofiltration at 35 mL/kg/h. 
Sample collection
Mass-transfer concept was used to evaluate the concentration 
of  cleared and absorbed antimicrobials. Indicative samples 
were taken after 12 or 24 h PK steady-state. Five samples 
were collected in both groups (at H1 [i.e., 1 h after 
antimicrobial infusion], H3, H6, H9 and at H12 or H24). 
Three samples were taken for each time period, one from 
the venous line after the filter, one from the effluent bag 
and one from the patient’s arterial catheter. As predilution 
was used, sampling before the filter was not applied. Time 
and total effluent volume in the bags were recorded for each 
sample. All plasma and ultrafiltrate samples were placed 
in 5 ml Vacutainer tubes and immediately centrifuged and 
frozen at -80°C until assayed. 
Sample assays
Plasma and ultrafiltrate concentrations of  anti-infective 
agents were determined with reversed-phase high-
performance liquid chromatography (HPLC) using an 
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adapted ultraviolet (UV) detection method.[13–15] Plasma 
samples were extracted by SPE? with Phenomenex 
Strata-X™ or Varian Plexa™ cartridges (for azoles) 
or ultra-filtered with Microcon™ devices. Dialysate/
ultrafiltrate samples underwent no extraction but were 
directly injected into the system. Chromatographic 
separation was performed on Prontosil AQ+ 150 x 
4.6 mm 5 µm columns (Bischoff), or on a Gemini C6-
phenyl 150 x 4.6 mm 5 µm column (Phenomenex) 
for azoles. Mobile phases used phosphate buffers (at 
pH between 3.5 and 7) and acetonitrile. TEA 0.04% 
at pH 2.7 replaced phosphate buffer for piperacilline/
tazobactam and ofloxacin. Wavelengths between 210 
and 320 nm were used for UV detection. All HPLC 
methods were validated according to bioanalytical FDA 
criteria.[16] Linezolid, imipenem, and ertapenem were used as 
an internal standard. Coefficients of  determination (r2) for 
the plasma assays over the standard curves concentration 
ranges were all above 0.99 with intercept close to zero 
for all studies. Within- and between-day coefficients of  
variation (CV) for plasma samples ranged respectively from 
0.84% to 2.52% and from 1.36% to 5.43% at the chosen 
quality control concentrations. Coefficients of  variation 
(r2) for the ultrafiltrate assays over the standard curves 
concentration ranges were all above 0.99 and intercept close 
to zero for all studies. Here, within- and between-day CV 
for ultrafiltrate samples ranged respectively from 0.78% 
to 2.43% and from 1.08% to 4.86% at the chosen quality 
control concentrations. Within- and between-day accuracy 
for the plasma and ultrafiltrate assays ranged respectively 
from 96.23% to 104.32% and from 98.24% to 102.68%. 
All assays had good sensitivity. Limit of  detection (LOD) 
and limit of  quantification (LOQ) were under minimal 
concentrations measured on patients. All HPLC assay 
parameters are summarized in Table 2.
Pharmacokinetic analysis
Plasma concentration-time data for all anti-infective agents 
were analyzed by standard PK methods using Kinetica™ 
software and an open one-compartmental model with first 
order elimination (Kinetica™ version 4.4 for Windows, San 
Diego, CA). Pre-membrane plasma drug concentrations 
were used to determine the PK parameters. The apparent 
terminal elimination rate constant (kel) was assessed by 
least-squares regression analysis of  the terminal portion 
of  the natural log concentration-time curve. Elimination 
half-life (t1/2) was calculated as 0.693/kel. Maximum plasma 
drug concentration (Cmax) was obtained at the end of  the 
drug infusion. Minimum plasma concentration (Cmin) was 
determined by direct measurement at the end of  the dosing 
interval. Steady-state concentration (Css) was determined 
at PK steady-state during continuous infusion. The area 
Table 1: Demographic characteristics
Demographic data All HV LV
Age (years) 66 ± 12 69 ± 9 63 ± 14
Height (cm) 169 ± 10 170 ± 8 167± 12
Weight (kg) 75 ± 18 77± 22 73 ± 13
Gender (M/F) 28/14 15/7 13/7
SAPS 2 63 ± 10 65 ± 8 61 ± 12
SOFA 12 ± 2 12 ± 2 12 ± 2
Protein 45 ± 8 45 ± 8 46 ± 9
Albumin 21 ± 4 21 ± 4 22 ± 3
Creatinine 243 ± 116 278 ± 128 196 ± 82
Pathology 42 22 20
Peritonitis 26 15 11
Sepsis 3 1 2
Mediastinitis 4 2 2
Pneumonia 4 1 3
Endocarditis 5 3 2
Urine output (24 h) 223 ± 167 195 ± 166 253 ± 167
Blood flow rate (mL/min) 278 ± 51 317 ± 37 234 ± 18
Ultrafiltration rate (mL/h) 3956 ± 1602 5221 ± 1137 2557 ± 433
28-day mortality 15 8 7
HV: High volume; LV: Low volume.
Breilh et al.: Pharmacokinetics and pharmacodynamics of anti-infective agents
158 JOURNAL OF TRANSLATIONAL INTERNAL MEDICINE / OCT-DEC 2019 / VOL 7 | ISSUE 4
under the concentration-time curve from time zero to 
the end of  the dosing interval (AUC0-τ) was calculated 
by the linear trapezoidal summation method. Since true 
PK steady-state conditions could not be assumed in all 
patients, volume of  distribution (Vd) was calculated by 
non-steady-state methods, which take into account the 
number of  doses previously administered. Total systemic 
clearance (CLS) was calculated by dose/AUC0-τ. During 
CVVH, drugs are predominantly cleared by convection 
but also in part by membrane adsorption. The sieving 
coefficient (Sc), the drug concentration in ultrafiltrate, 
was calculated as 2 × Cuf/(Ca + Cv), where Cuf  is the drug 
concentration in ultrafiltrate, Ca – the drug concentration 
in pre-membrane plasma (i.e., plasma obtained from the 
arterial line in predilution), and Cv – the drug concentration 
in post-membrane plasma. Clearance of  drug across the 
membrane during CVVH (CLCVVH) was calculated by 
CS × Quf  x dilution factor (dilution factor = blood flow 
(Qb) / (Qb + predilution flow (Qs pre) with Qs pre = 
volume infused in predilution). The percentage of  CLS 
attributed to CLCVVH (%CLS) is calculated as (CLCVVH/
CLS) × 100. Non-renal clearance (CLNR), which is mainly 
the residual renal and hepatic clearance, was calculated as 
CLS - CLCVVH as urine output in the study population was 
negligible. All calculations were made by programming PK 
and CVVH clearance equations into Microsoft Excel 2003 
(Microsoft Corporation, Redmond, WA) spreadsheets. 
Using Excel, measures of  central tendency and variability 
were evaluated for all patient and CVVH characteristics, PK 
parameters, and CVVH clearance. European Committee 
on Antimicrobial Susceptibility Testing (EUCAST) 
breakpoints were used to define micro-organism resistance.
PK/PD analysis
General PK/PD principles were considered and their 
clinical application and dosing implications for critically 
ill patients addressed. The time during which plasma 
concentrations of  free drug are above the minimal 
inhibitory concentration (MIC) of  the infecting pathogen 
(T > MIC) was then calculated as natural log (maximum 
bacterial population size. (Cfumax ) /CMIC)/kel, where CMIC 
is the MIC for the organism. The percent T% > MIC was 
determined by (T > MIC/τ) × 100, where τ is the dosing 
interval. Target goal for T% > MIC was > 40 to 50% for 
Table 2: HPLC assays parameters.










Ertapenem Prontosil AQ+ Na2HPO4




Imipenem Prontosil AQ+ Na2HPO4




Doripenem Prontosil AQ+ Na2HPO4




Ceftriaxone Prontosil AQ+ Na2HPO4






Prontosil AQ+ TEA 0,04%




Ofloxacine Prontosil AQ+ TEA 0,04%




Linezolid Prontosil AQ+ KH2PO4




Daptomycine Prontosil AQ+ Na2HPO4




Metronidazole Prontosil AQ+ Na2HPO4


















SPE: Solid phase extraction; ACN: acetonitrile; λ = wavelength; LOD: limit of detection; LOQ: limit of quantification.
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clinical efficacy and prevention of  resistance. The inhibitory 
quotient (IQ) corresponding to the Cmax/MIC ratio and 
the inhibitory area under the curve (AUIC) corresponding 
to the AUC/MIC ratio were calculated. Target goals for 
IQ and AUIC were > 4 and > 125 respectively for clinical 
efficacy and prevention of  resistance especially for Gram-
negative organisms and for concentration-dependent 
antibiotics. MICs of  antibiotics for isolated pathogens were 
determined by the local clinical microbiology laboratory. 
Predicted T% > MIC for dosing regimens not observed in 
the study patients were calculated based on PK parameters 
derived from the individual patients within both CVVH 
groups. 
Statistical analysis
Differences between demographic variables among patients 
receiving either HV- or SV-CVVH were assessed by one-
way analysis of  variance fixed-effects model for continuous 
variables or by two-way chi-square test for categorical 
variables. Differences among calculated PK parameters 
were assessed by the two-tailed Mann-Whitney rank sum 
test for unpaired non-parametric data. Correlations between 
PK variables were determined using the  Spearman’s 
rank correlation coefficient for non-parametric data. All 
statistical tests were performed with the Statistica™ version 
6.1 for Windows (Statistica™ Software, San Diego, CA). P 
values ≤ 0.05 were considered to be significant.
RESULTS
Forty-five patients were studied for four consecutive 
days. During this study period, 5 patients received one, 
34 patients received two, and 6 patients received three 
antimicrobial agents. Characteristics of  the patients are 
shown in Table 1. Two patients died in the first few hours 
of  treatment and the samples of  one patient were damaged 
during transportation. Thus, 42 patients were evaluable. 
Mean arterial plasma and effluent concentrations of  the 
anti-infective agents in both CVVH groups are illustrated in 
Figure 1. The PK parameters are presented in Tables 3 and 
3 bis. All agents were easily filtered. Mean Sc ranged from 
38.70% to 96.70%. Mean t1/2 of  all agents during HV-
CVVH (from 1.29 to 28.54 h) was significantly shorter than 
during SV CVVH (from 1.51 to 33.85 h) (P < 0.05). CLs, 
CLCVVH , and CLNR of  all agents were significantly higher 
during HV-CVVH than during SV-CVVH (P < 0.05). Renal 
excretion of  all agents ranged between 13% and 100% 
and 9% and 57% for respectively HV- and SV-CVVH. 
Drug removal was moderate with SV-CVVH but became 
significantly enhanced by HV-CVVH due to increased 
ultrafiltrate flow. Drug half-live was extended, probably 
because of  a sepsis-induced Vd increase in most patients. 
Irrespective of  the antimicrobial agent, PK parameters 
were similar to those observed in infected patients without 
impaired renal function. The PK/PD parameters (Table 4) 
demonstrated that treatments met efficiency targets for 
T% > MIC and IQ. Finally, a significant correlation existed 
between Quf  and CLS (Spearman test: P < 0.005) and 
between CLCVVH and elimination half-life (Spearman test: 
P < 0.005).
DISCUSSION
Antimicrobial clearance during CRRT is determined 
by several chemical drug characteristics.[17] Molecular 
weight and drug solubility are no limiting factors since 
antimicrobials are mostly small hydrophilic molecules.[18,19] 
Drug Vd may increase significantly during resuscitation of  
septic shock. Thus, extracellular water and by extension 
current body weight must be considered to optimize the 
dose of  certain antibiotic classes (e.g., aminoglycosides).[20] 
Protein binding remains the most important factor limiting 
antimicrobial elimination by convective CRRT.[21] Protein-
bound molecules do not pass the pores of  the currently 
used dialysis membranes. However, protein binding in 
critically ill patients may be highly variable. An increase in 
unbound drug will increase Sc and Sd, and hence, clearance 
by CRRT.[22] Based on the aforementioned, antimicrobial 
drugs can be categorized as “highly”, “moderately” or “not 
at all” eliminated by CRRT. 
Antimicrobial agents have three “killing profiles”: time-
dependent, concentration-dependent, or a combination 
of  both. These profiles determine the drug dosing to 
obtain maximum therapeutic efficacy at minimal risk for 
the development of  resistance and toxicity.[23] CLNR was 
significantly higher for all agents during HV-CVVH as 
compared with SV-CVVH, which is somewhat unexpected 
because of  the augmented CLCVVH in the HV-CVVH group. 
Drugs highly influenced by CRRT 
Time-dependent killing
The β-lactams (penicillins, cephalosporins, carbapenems 
and monobactams) are small hydrophilic molecules and 
thus likely to be significantly cleared by CRRT. They 
exhibit time-dependent killing and have a slow continuous 
bactericidal effect. Killing is most related to the time during 
which serum concentration exceeds 1 to 5 times the MIC 
and, in part, also to a continued suppression of  bacterial 
growth even when drug concentrations fall below MIC (i.e., 
the post-antibiotic effect).[24] To obtain maximal bactericidal 
activity, a T > MIC of  50 to 60% is required for penicillins 
and monobactams, 60 to 70% for cephalosporins and 40% 
for carbapenems.
Piperacillin-tazobactam
Mueller et al. investigated the PK of  piperacillin-tazobactam 
in anuric patients treated with CVVHD. The elimination 
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continuedFigure 1: Evolution of arterial plasma concentrations and effluent versus time for anti-infective agents in IVOIRE study during high volume CVVH (HD) and standard 
volume CVVH (BD)
half-life of  piperacillin was 4.3 ± 1.2 h, and that of  
tazobactam 5.6 ± 1.3 h. The contribution of  CVVHD to the 
overall elimination was relevant (> 25%) for both drugs.[25] 
A recent study in critically ill patients on CVVHDF 
receiving piperacillin-tazobactam (4 g/0.5 g) every 8 h 
showed a total clearance of   5.1 (4.2–6.2) L/h and 3.8 
(3.3–4.2) L/h and a CVVHDF clearance of  2.5 (2.3–3.1) 
L/h and 2.5 (2.3–3.2) L/h for piperacillin and tazobactam, 
respectively.[26] In patients treated with CVVHDF and 
receiving a 4 h infusion of  piperacillin 4 g / tazobactam 
0.5 g every 8 h, Awissi et al. found a median total clearance 
of  65.82 mL/min (53.79–102.87), and a median renal 
clearance of  0.16 mL/min (0.05–3.04). Median CRRT dose 
was 32.0 mL/kg/h (25.0–39.8).[27] Although some studies 
suggest a better outcome in critically ill patients receiving 
prolonged infusion, the level of  evidence is moderate.[28] 
In our study, the in vivo concentration obtained after a 
daily high dose (16 g) continuous but not bolus infusion 
of  piperacillin was adequate, stable throughout time, and 
within the recommended range for efficacy even in HV-
CVVH treated patients. This underscores that piperacillin 
treatment during CRRT is most efficacious when 
administered as a loading dose followed by continuous 
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Table 3A: Pharmacokinetic parameters for all studied antimicrobials

















Ertapenem HD 5 1000 24 17.28 5.75 - 181.90 35 4.41
Ertapenem BD 2 1000 24 32.39 17.86 - 327.23 30 6.79
Imipenem HD Intermittent infusion 4 500 6 13.00 2.10 - 144.88 25.60 1.29
Imipenem BD  Intermittent infusion 4 500 6 15.30 3.35 - 209.88 20.70 1.51
Imipenem HD Continuous infusion 2 2000 24 1.43 (D*) 0.78 (D*) 2.74 - - -
Imipenem BD Continuous infusion 5 2000 24 4.96 (D*) 2.33 (D*) 7.19 - - -
Doripenem HD 3 500 8 10.16 4.29 - 65.56 33.67 2.59
Doripenem BD 7 500 8 12.82 5.62 - 80.98 52.61 4.21
Ceftriaxone HD 2 2000 24 225.62 5.16 - 235.32 51.32 4.19
Ceftriaxone BD 4 2000 24 283.65 6.85 - 415.37 40.13 5.76
Piperacillin HD Intermittent infusion 5 4000 6 145.62 35.56 - 122.52 38.29 3.61
Piperacillin BD  Intermittent infusion 2 4000 6 78.35 39.82 - 147.63 50.99 3.99
Piperacillin HD  Continuous infusion 10 16000 24 91.62 (D*)66.38 (D*) 158.71 90.47 - -




256.54 42.74 - -
Ofloxacin HD 14 200 12 8.47 3.38 - 64.73 32.54 6.58
Ofloxacin BD 8 200 12 8.77 2.44 - 52.02 51.46 8.72
Linezolid HD 2 600 12 17.55 6.68 - 129.63 46.76 6.33
Linezolid BD 3 600 12 21.50 4.30 - 131.31 30.70 4.59
Daptomycin HD 4 6 mg/kg 24 55.22 7.53 - 477.72 20.26 8.53
Daptomycin BD 7 6 mg/kg 24 54.93 10.91 - 510.99 17.70 11.94
Metronidazole HD 12 500 8 15.97 10.61 - 262.57 42 8.22
Metronidazole BD 12 500 8 18.63 10.72 - 236.17 54 10.18
Fluconazole HD 2 400 12 17.40 9.10 - 114.39 73.38 28.54
Fluconazole BD 1 400 12 14.60 7.60 - 96.44 103.71 33.85
Voriconazole BD 3 3 mg/kg 12 7.37 4.79 - 55.00 65.55 7.19
Vd = CLs/Kel; Kel = Ln2/T1/2Kel; T1/2Kel = elimination half-life; D* = loading dose; Vd = volume of distribution; T1/2   = elimination half-life; τ = time interval 
between two administrations; Cmax = maximum arterial concentration at the end of infusion; Cmin = trough arterial concentration; Css = the steady-state 
arterial concentration for continuous infusion; AUC0-τ = area under the curve for plasma concentrations between 0 and τ; n = number of patients.
Imipenem
Fish et al. studied the PK of  imipenem during CVVH and 
continuous veno-venous hemodiafiltration (CVVHDF). 
Mean CLs and elimination half-life (t1/2) of  imipenem 
were 145 ± 18 mL/min and 2.7 ± 1.3 h during CVVH 
and 178 ± 18 mL/min and 2.6 ± 1.6 h during CVVHDF, 
respectively. Imipenem clearance was substantially 
increased during both CVVH and CVVHDF, with 
membrane clearance representing respectively 25% and 
32% of  CLs.[30] We found mean imipenem SC, CLCVVH and 
t1/2 ranging from 52.40 to 80.70%, 16.67 to 65.25 mL/
min, and 1.29 to 1.51 h respectively. Total clearances were 
higher than previously published (158.82 to 506.83 mL/
min) with membrane clearance ranging from 9% to 18%. [31]
Ertapenem and doripenem
The newer carbapenems ertapenem and doripenem are 
more stable after reconstitution and have a longer t1/2. 
Mistry et al. showed that hemodialysis cleared approximately 
30% of  the ertapenem dose.[32] Hidaka et al. showed that 
total body clearance of  doripenem was 58.0 ± 12.7 mL/
min, including 13.5 ± 1.6 mL/min CVVHDF clearance. 
Mean t1/2 of  doripenem was 7.9 ± 3.7 h. Thus, under 
the conditions tested, CVVHDF appeared to have little 
effect on doripenem clearance. Therefore, serum levels 
of  doripenem during CVVHDF can be controlled by 
adjustment of  dose and dosing interval in accordance with 
residual renal function.[33] Cirillo et al. showed that both 
CVVH and CVVHD efficiently removed doripenem with an 
SC of  respectively 67% and 76%.[34] We demonstrated that, 
despite acceptable in vivo concentrations of  ertapenem or 
doripenem after bolus or continuous infusion, a prolonged 
(4 h) bolus or continuous infusion may be beneficial to 
keep concentrations longer above MIC.  From our study, 
it can be concluded that imipenem should be replaced 
by doripenem or meropenem during CRRT. A higher 
meropenem dose (i.e., 3000 to 6000 mg), may be most 
adequate whilst preventing resistance of  pathogens with 
MICs between 4 and 8 µg/mL, in particular, Pseudomonas 
aeruginosa strains. Continuous infusion of  meropenem 
preferred mode because the drug is stable for 8 h.[35]
Linezolid
Meyer et al. showed that linezolid PK during CVVH was 
comparable to that of  healthy subjects and patients without 
renal impairment. The t1/2, total clearance and hemofiltration 
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Ertapenem HD 91.63 55.90 95.83 77 41.50 45 50.13
Ertapenem BD 50.93 38.70 42.67 84 13.93 27 37
Imipenem HD Intermittent infusion 230.08 66.90 75.83 80 40.58 18 189.50
Imipenem BD  Intermittent infusion 158.82 71.60 32.50 86 20.01 13 138.80
Imipenem HD Continuous infusion 506.83 80.70 105.00 77 65.25 13 441.58
Imipenem BD Continuous infusion 193.16 52.40 37.00 86 16.67 9 176.49
Doripenem HD 150.38 90.1 102.00 84 77.20 51 73.18
Doripenem BD 144.33 75.60 32.00 80 19.35 13 124.98
Ceftriaxone HD 141.65 49.60 86.58 88 37.79 27 103.86
Ceftriaxone BD 80.25 64.60 35.24 79 17.98 22 62.27
Pipéracillin HD Intermittent infusion 122.52 96.70 103.05 88 87.69 72 34.83
Pipéracillin BD  Intermittent infusion 147.63 92.56 35.50 82 29.94 18 117.69
Pipéracillin HD  Continuous infusion 90.48 70.50 98.50 86 59.72 66 30.76
Pipéracillin BD  Continuous infusion 42.74 80.10 30.00 80 19.22 45 23.52
Ofloxacin HD 56.93 59.50 102.00 86 52.19 92 49.44
Ofloxacin BD 68.18 66.00 35.50 80 18.74 28 4.74
Linezolid HD 84.94 76.20 102.00 77 59.84 70.50 55.48
Linezolid BD 77.26 80.50 33.00 82 21.78 28 25.10
Daptomycin HD 27.42 12.50 105.00 88 11.55 42 15.87
Daptomycin BD 17.11 15.80 37.00 85 4.97 29 12.14
Metronidazole HD 59.09 82.10 92.00 78 58.91 100 19.78
Metronidazole BD 61.22 89.30 37.00 80 26.43 43 0.18
Fluconazole HD 29.35 59.20 85.00 80 26.05 89 14.79
Fluconazole BD 34.57 75.40 32.00 82 19.78 57 0.30
Voriconazole BD 105.31 40.50 35.00 88 12.47 12 92.84
CLCVVH = Cs x QUF x dilution factor = convection clearance; dilution factor = Qblood/(Qblood + Qinf); Qinf is the infusion rate of the substitution fluid; CLS = total 
body clearance; CS = Sieving coefficient = 2 x CUF / (Cpre + Cpost); CUF = the drug concentration in ultrafiltrate; Cpre = the drug concentration in prefilter 
serum corrected for predilution; Cpost = the drug concentration in postfilter serum; n = number of patients; CLNR = non renal clearance = CLS - CLCVVH.
clearance were 4.3 ± 1.7 h, 9.3 ± 3.5 L/h and 1.9 ± 0.8 L/h, 
respectively.[36] Pea et al. identified significant elimination of  
linezolid in patients undergoing CVVH. Total clearance was 
25% higher and serum trough concentration 50% lower. In 
93% of  the patients, serum concentrations above MIC were 
obtained after the administration of  a standard dose (600 mg 
every 12 h) of  linezolid. However, the mean T% MIC was 
only 57% of  the dosing interval for pathogens with a MIC of  
4 mg/L. Thus, 600 mg of  linezolid every 8 h may be necessary 
to assure optimal antibacterial activity.[37]
We suggest that, whenever possible, time-dependent 
antibiotics should be administered in continuous infusion 
during CRRT. As the risk of  overdosing is limited and to 
avoid underdosing, higher than currently recommended 
doses should be prescribed, particularly when the range 
of  therapeutic concentrations is large.[19]
Drugs moderately influenced by CRRT (or when CVVH 
clearance largely contributes to total body clearance in AKI) 
In this category, antibiotic clearance is close to normal 
clearance in patients without AKI. Standard doses may be 
sufficient for optimal treatment.
Concentration-dependent killing
Metronidazole
In patients undergoing dialysis, plasma t 1/2 of  
metronidazole was 6.8 h, which is comparable with 
healthy subjects. Dialysis clearance of  metronidazole 
was 60 mL/min with 25% drug eliminated at the start of  
treatment.[38] Kreeft et al. found that plasma metronidazole 
concentrations in patients with renal insufficiency were 
similar to those in patients with normal renal function. 
Moreover, renal insufficiency did not affect beta half-life 
(6.5 h) or plasma clearance (10.1 L/h) of  metronidazole.[39] 
In our study, mean metronidazole SC, CLCVVH and t1/2 
ranged from 82.10 to 89.30%, 26.43 to 58.91 mL/min, and 
8.22 to 10.18 h respectively. Accordingly, a dose of  1500 
mg once daily is proposed. The currently prescribed dose 
of  500 mg three times daily should be abandoned! 
Ofloxacin
During CVVH, Fuhrmann et al. found a mean serum 
ofloxacin concentration peak of  5.5 ± 0.7 mg/L and a t1/2, 
hemofiltration clearance, and total removal of  2.8 ± 0.5 h, 
89.9 ± 4.5 mL/min, and 76.9% ± 7.1%, respectively.[40] In 
our study, mean ofloxacin SC, CLCVVH and t1/2 ranged 
from 59.50 to 66.00%; 18.74 to 52.19 mL/min and 6.58 to 
Breilh et al.: Pharmacokinetics and pharmacodynamics of anti-infective agents
164 JOURNAL OF TRANSLATIONAL INTERNAL MEDICINE / OCT-DEC 2019 / VOL 7 | ISSUE 4
Table 4: PK/PD parameters for all studied antibiotics
Antibiotic Isolated Pathogen MIC (µg/mL) T% > MIC IQ = Cmax/CMI or Css/CMI
Imipenem Pseudomonas aeruginosa (1) 3 34 4
Escherichia coli (1) 1 57 11
Enterococcus faecalis (1) 3 37 4
Streptococcus sp. (1) 2 57 9
Klebsiella pneumoniae (1) 0.5 85 23
Pseudomonas aeruginosa (2) 1 43 13
Enterobacter cloacae (1) 2 65 6
Ofloxacin Klebsiella oxytoca (1) 0.3 - 17
Moraxella catarrhalis (1) 0,25 - 22
Enterobacter cloacae(2) 0,25 - 46
Moraxella catarrhalis (2) 0.3 - 36
Pseudomonas  aeruginosa (3) 2 - 5
Escherichia coli (3) 1 - 6
Serratia sp. 1 - 6
Piperacillin Enterobacter cloacae (3) 3 100 11
Stenotrophomonas maltophila 12.5 84 10
Streptococcus sp. (2) 0,05 100 700
Escherichia coli (4) 1 100 49
Acinetobacter baumanii (1) 9 100 4
Enterobacter cloacae (4) 3 100 11
Klebsiella oxytoca (2) 14 100 9
Pseudomonas aeruginosa (4) 2 100 20
Escherichia coli (5) 26 58 5
Proteus mirabilis 0,06 100 583
Acinetobacter baumanii (2) 4 80 9
Escherichia coli (6) 0.2 100 159
Streptococcus haemolysis 0,05 65 10
Enterobacter aerogenes (1) 1 100 49
Ceftriaxone Escherichia coli (7) 0,02 100 10000
Enterococcus faecalis (4) 6 48 35
Escherichia coli (8) 0,02 83 10000
Enterococcus faecalis (5) 0.3 58 588
Ertapenem Klebsiella oxytoca (3) 0,2 100 50
Enterobacter cloacae (5) 0,1 100 100
Escherichia coli (9) 0.5 80 200
Enterobacter cloacae (6) 1 90 100
Klebsiella oxytoca (4) 0.5 90 200
Enterobacter cloacae (7) 1 78 100
Klebsiella oxytoca (5) 0,06 100 1667
Linezolid Staphylococcus aureus (1) 2.50 32 8
Staphylococcus aureus (2) 1 90 20
Staphylococcus aureus (3) 0.5 80 40
Doripenem Enterobacter cloacae (8) 1 12
Enterobacter aerogenes (2) 0,03 100 375
Acinetobacter baumanii (3) 2 88 6
Pseudomonas aeruginosa (5) 1 100 12
Pseudomonas aeruginosa (6) 2 100 6
Pseudomonas aeruginosa (7) 1 100 12
Enterococcus faecalis (6) 1.5 80 9
Daptomycin Staphylococcus aureus (4) 0.5 100 110
Staphylococcus aureus (5) 1 90 55
Enterococcus faecalis (2) 1 88 55
Enterococcus faecalis (3) 1 70 55
Metronidazole Bacterioides fragilis (1) 0.5 90 20
Bacterioides fragilis (2) 0.5 90 20
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8.72 h, respectively. However, due to the high volume of  
distribution, serum concentration is comparable between 
the standard and high volume group, implying that no 
dose adaptation is required at increasing CVVH dose. 
Choi et al. [41] studied levofloxacin in an in vitro CVVH model 
and found significantly less drug adsorption on a polyamide 
than on a polyacrylonitrile (PAN) filter. Polyethersulfone used 
in our study has a pretty bad record regarding almost no drug 
adsorption.[42] Post-dilution resulted in a small but statistically 
significant decrease in SC when a PAN filter was used. 
Time-dependent killing
Fluconazole
Fluconazole has a low protein binding and a low molecular 
weight. About 80% is eliminated unchanged by the 
kidneys. Fluconazole is effectively cleared by hemodialysis 
and hemofiltration.[43–44] Pittrow and Penk showed that 
patients undergoing CRRT require a similar loading dose 
of  fluconazole as patients with normal renal function. 
Thereafter, a maintenance dose is given adjusted for anuria 
by multiplying with a factor accounting for extracorporeal 
elimination of  the absorbed dose.[45] Yagasaki et al. found 
that continuous hemodiafiltration is highly effective for 
fluconazole removal. Fluconazole should be administered 
at a dose of  500 to 600 mg every 12 h [46] but close hepatic, 
neurological, and ECG (QT interval!) monitoring is 
mandatory. Bergner et al. measured plasma fluconazole 
concentrations during CVVHDF.[46] All patients reached 
levels between 16 and 32 mg/L, which remained in this 
range for minimal 1 and up to 24 h (on average 9.6 h at 
an UF rate of  2000 mL/h and 15.7 h at an UF rate of  
1000 mL/h). Thus, a once-daily dose of  800 mg fluconazole 
is necessary to achieve optimal fungicidal activity.[47] CVVH 
effectively removes fluconazole from the circulation 
by a clearance into the hemofiltrate of  approximately 
21 mL/min. This implies no dose reduction during 
CVVH.[48] Muhl et al. compared the elimination of  
fluconazole during continuous veno-venous hemodialysis 
(CVVHD) and CVVH at different dosages. Extracorporeal 
clearance (CVVHD 30.5 mL/min, CVVH 17.5 mL/min) 
and total clearance of  fluconazole (CVVHD 37.9 mL/
min, CVVH 25.3 mL/min) were significantly higher 
during CVVHD. During CVVHD, the sieving coefficient 
(S) (CVVHD) was 0.88 and t1/2 was 14.8–35.1 h. During 
CVVH, the S(CVVH) was 0.96 and t1/2 was 24.0–51.6 h. 
Since CVVHD clearance may considerably exceed 
the clearance in patients with normal renal function, a 
daily dose of  400 to 800 mg is recommended during 
CVVHD.[49] In our study, mean fluconazole SC, CLCVVH and 
t1/2 ranged from 59.20 to 75.40%, 19.78 to 26.05 mL/
min, and 28.54 to 33.85 h, respectively. Taken together, 
fluconazole should be administered at a dose of  500 to 
600 mg every 12 h.[46] Point of  care dosing of  fluconazole 
could be an interesting option.[50]
Drugs not influenced by CRRT
Time dependent killing
Ceftriaxone
Ceftriaxone clearance in patients receiving CVVHD is 
equivalent to clearance in subjects with normal renal 
function. Therefore, no dose adjustment is necessary.[51,52] 
In hemodialyzed patients, administration of  2 g ceftriaxone 
resulted in a T > MIC of  88.5 (78.8–98.3) h and 17.7 (13.3–
22.0) h for MIC breakpoints of  1 and 8 mg/L, respectively.[53] 
See comment in PubMed Commons belowIn patients with 
various degrees of  renal impairment, Patel et al. confirmed 
the PK efficacy of  a 2 g ceftriaxone dose. T1/2 (group 
mean ranged from 11.7 to 17.3 h) and plasma clearance 
(group mean ranged from 529 to 705 ml/h) showed no 
correlation with creatinine clearance.[54] In our study, 
Table 5: Dose recommendations for some frequently used antimicrobials during CRRT (CVVH,  25 mL/kg/h)
Antimicrobial Loading dose Maintenance dose
Amikacin 30-35 mg/kg TDM
Meropenem 2 g 2 g over 3 h tid
Piperacillin-tazobactam 4 g/0.5 g 16 g/2 g (CI)
Vancomycin 35 mg/kg over 4 h 30 mg/kg (TDM = 25–30 mg/L)
Teicoplanin 15 mg/kg bid 600 mg od
Linezolid  600 mg tid
Ciprofloxacin 800 mg 400 mg tid
Tigecyclin 150 mg 100 mg bid
Colistin 9 MIU 4.5 MIU tid
Voriconazole 8 mg/kg bid 6 mg/kg bid
Fluconazole  600 mg bid
Cefepime  2 g tid
Gentamycin  7 mg/kg od
Bactrim 1200 mg/240 mg (3 amp) 800 mg/160 mg (2 amp) tid
Clindamycin  900 mg qid
TDM = therapeutic drug monitoring; od = once daily; bid = twice daily; tid = three times daily; qid = four times daily; amp = ampules; CI = continuous 
infusion; MIU = million units. According to references No. 68-77 – Adapted and changed from reference No. 63.
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mean ceftriaxone SC, CLCVVH and t1/2 ranged from 49.60 




Salama et al. obtained sufficient pre-hemodialysis serum 
concentrations after thrice-weekly post-hemodialysis 
administration of  6 mg/kg daptomycin even after a 68 
h interval between dialysis sessions.[55] Mean urea and 
daptomycin reduction ratios were 79.6 ± 5.8% and 57.6 ± 
9.2%, respectively. Daptomycin half-life was 19.4 ± 6.5 and 
3.8 ± 1.1 h “off ” and “on” hemodialysis, respectively, with 
minimal rebound 1 h post-hemodialysis. Churchwell et al. 
studied transmembrane clearance of  daptomycin during 
CVVH and CVVHD in an in vitro model that employed 
AN69 and polysulfone hemodiafilters at varying ultrafiltrate 
and dialysate flow rates. Clearance depended on filter type 
and dialysate and ultrafiltration rates. High ultrafiltrate 
or dialysate rates resulted in substantial daptomycin 
clearance.[56] Corti et al. found no significant accumulation 
of  daptomycin when a dose of  6 mg/kg was given to 
patients undergoing CRRT with an effluent flow rate 
> 30 mL/kg/h.[57] In our study, mean daptomycin SC, 
CLCVVH and t1/2 ranged from 12.50 to 15.80%, 4.97 to 
11.55 mL/min and 8.53 to 11.94 h, respectively. 
Voriconazole
Being poorly water-soluble, the intravenous voriconazole 
formulation includes the vehicle sulfobutylether-beta-
cyclodextrin sodium (SBECD).  SBECD is not protein-
bound and predominantly eliminated by glomerular 
filtration. Intravenous voriconazole is not recommended in 
patients with a creatinine clearance < 50 mL/min because 
of  potentially toxic accumulation of  SBECD.[58] Tyree et al. 
recently showed that CVVH effectively removed SBECD 
at a rate similar to the ultrafiltration rate.[59] Voriconazole 
clearance by CVVH was not clinically significant. Standard 
doses of  intravenous voriconazole can be used safely 
in patients undergoing CVVH. Quintard et al. studied 
voriconazole PK during HV-CVVH. See comment in 
PubMed Commons belowThe total body clearance of  
voriconazole was 5.4 L/h with a half-life of  16.5 h and 
a distribution volume of  128.6 L. The estimated SC was 
0.58 and the filtration clearance 1.39 L/h. HV-CVVH 
may affect voriconazole disposition more than other 
techniques.[60,61] When voriconazole doses mount to 6 
mg/kg per 12 h, intermittent hemodialysis may fail to 
completely eliminate SBECD. CRRT is then recommended 
to avoid vehicle-induced toxicity.[61,62]
STUDY LIMITATIONS
The current study has major flaws and limitations. First, 
therapeutic drug monitoring remained observational 
and was not applied to improve PK/PD of  the studied 
antimicrobials. Evaluating the impact of  many relevant 
patient- and technique-related variables influencing PK/
PD (i.e., distribution volume, membrane type, MIC of  
the micro-organisms, quality of  resuscitation)[63–65] also 
remained beyond the scope of  the study. Second, at 
the time of  study, all patients received unfractionated 
heparin for extracorporeal circuit anticoagulation. Today, 
regional citrate anticoagulation is increasingly used. 
Citrate better preserves porosity and adsorptive capacity 
of  the membrane, which inherently results in different 
antimicrobial elimination.[64,66] Third, non-adsorptive 
membranes were used, which have been progressively 
supplanted by highly adsorptive membranes. The latter 
more effectively eliminate antimicrobials through bulk 
rather than surface adsorption.[64,67,68] Finally, data were 
gathered during HV-CVVH, which did not prove to be 
superior to SV-CVVH.[11] 
CONCLUSIONS & PERSPECTIVES 
As expected, HV-CVVH eliminated more antibiotics than 
SV-CVVH. All agents were easily filtered. Mean elimination 
t1/2 of  all agents was significantly shorter during HV-
CVVH than during SV-CVVH. CLs, CLCVVH, and CLNR 
of  all agents were significantly higher during HV-CVVH. 
Antibiotics that are highly removed by CRRT should be 
preferentially administered as a continuous infusion. A 
loading dose of  4 g followed by a continuous infusion 
of  16 g provides the most optimal PK for piperacillin. 
Regarding carbapenems, our results argue against the use 
of  imipenem during CRRT. Doripenem or meropenem 
are better options. A meropenem dose of  3 to 6 g is 
required to adequately treat pathogens with MICs between 
4 to 8 mg/L, especially Pseudomonas aeruginosa strains. As 
meropenem was found to be stable for 8 h, it can be 
given as a continuous perfusion. In almost all patients, 
linezolid concentrations above the MIC were obtained after 
administration of  a standard dose (600 mg every 12 h) but 
optimal antibacterial activity at a MIC of  4 mg/L requires 
600 mg linezolid every 8 h. 
During CRRT, the “classical” 500 mg three times daily 
metronidazole dose should be abandoned and replaced by 
a 1500 mg once daily dose. The dose of  fluconazole must 
be increased to 500 to 600 mg every 12 h. When higher 
doses of  voriconazole (up to 6 mg/kg per 12 h) are needed, 
intermittent hemodialysis should be replaced by CRRT to 
avoid toxicity induced by the SBECD vehicle.
CRRT significantly influences the PK/PD behavior of  
most antimicrobial agents. This is insufficiently anticipated 
by the current dosing guidelines. Patients are particularly at 
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risk for underdosing, which may cause treatment failure and 
enhance resistance. Table 5 depicts dose recommendations 
for some major antibiotic and antifungal drugs during 
CVVH (at a dose of  25 mL/kg/h) that are based upon 
relevant literature data [69–77] and our own findings.
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